Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 17:13:355.
doi: 10.3389/fnins.2019.00355. eCollection 2019.

Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment

Affiliations

Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment

Jiaen Ye et al. Front Neurosci. .

Abstract

Dopaminergic system dysfunction is involved in schizophrenia (SCZ) pathogenesis and can mediate SCZ-related motor disorders. Recent studies have gradually revealed that SCZ susceptibility and the associated motor symptoms can be mediated by genetic factors, including dopaminergic genes. More importantly, polymorphisms in these genes are associated with both antipsychotic drug sensitivity and adverse effects. The study of genetic polymorphisms in the dopaminergic system may help to optimize individualized drug strategies for SCZ patients. This review summarizes the current progress about the involvement of the dopamine system in SCZ-associated motor disorders and the motor-related adverse effects after antipsychotic treatment, with a special focus on polymorphisms in dopaminergic genes. We hypothesize that the genetic profile of the dopaminergic system mediates both SCZ-associated motor deficits associated and antipsychotic drug-related adverse effects. The study of dopaminergic gene polymorphisms may help to predict drug efficacy and decrease adverse effects, thereby optimizing treatment strategies.

Keywords: antipsychotic drugs; dopaminergic transmission; gene polymorphism; pharmacogenetics; schizophrenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Current working model for regulation of dopaminergic system and the effect of genetic polymorphism on motor dysfunction and antipsychotic drug-related motor deficits in SCZ patients.

Similar articles

Cited by

References

    1. Abboud R., Noronha C., Diwadkar V. A. (2017). Motor system dysfunction in the schizophrenia diathesis: neural systems to neurotransmitters. Eur. Psychiatry 44, 125–133. 10.1016/j.eurpsy.2017.04.004 - DOI - PMC - PubMed
    1. Abi-Dargham A. (2014). Dopamine dysfunction in schizophrenia. Schizophr. Res. 160, e6–e7. 10.1016/j.schres.2014.09.069 - DOI
    1. Bernagie C., Danckaerts M., Wampers M., De Hert M. (2016). Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-analysis. CNS Drugs 30, 807–818. 10.1007/s40263-016-0367-y - DOI - PMC - PubMed
    1. Bilic P., Jukic V., Vilibic M., Savic A., Bozina N. (2014). Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene 543, 125–132. 10.1016/j.gene.2014.03.050 - DOI - PubMed
    1. Birnbaum R., Weinberger D. R. (2017). Genetic insights into the neurodevelopmental origins of schizophrenia. Nat. Rev. Neurosci. 18, 727–740. 10.1038/nrn.2017.125 - DOI - PubMed

LinkOut - more resources